Wellington Management Group LLP Invests $20.02 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Wellington Management Group LLP purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 223,811 shares of the medical equipment provider's stock, valued at approximately $20,022,000. Wellington Management Group LLP owned about 0.32% of Lantheus at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Reinhart Partners LLC. boosted its holdings in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Swedbank AB increased its position in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after purchasing an additional 385,000 shares during the period. Raymond James Financial Inc. acquired a new position in Lantheus during the 4th quarter worth approximately $36,183,000. Finally, Boston Partners raised its stake in shares of Lantheus by 57.5% during the 4th quarter. Boston Partners now owns 400,797 shares of the medical equipment provider's stock worth $36,201,000 after buying an additional 146,268 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Up 3.5 %

NASDAQ:LNTH traded up $3.49 on Friday, reaching $102.00. The stock had a trading volume of 732,023 shares, compared to its average volume of 955,016. The stock has a fifty day moving average price of $94.00 and a 200-day moving average price of $95.62. Lantheus Holdings, Inc. has a 1-year low of $59.56 and a 1-year high of $126.89. The company has a market capitalization of $6.98 billion, a P/E ratio of 16.97 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LNTH shares. JMP Securities restated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial boosted their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. Finally, B. Riley reduced their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.